Article

Figures for Interest Grows in Treatment of Mood Disorders by Classic Psychedelics

Author(s):

Nicole Ledwos, MSc,M. Ishrat Husain, MD (Res), MBBS, MRCPsych

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."

Table. Registered Clinical Trials on ClinicalTrials.gov

Table. Registered Clinical Trials on ClinicalTrials.gov

Related Videos
Related Content
depression
December 18th 2024

IV Psilocin Benzoate for Major Depressive Disorder: New Phase 2a Results

Leah Kuntz
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder
December 17th 2024

First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder

Megan McSweeney
Blue Light, Depression, and Bipolar Disorder
August 4th 2021

Blue Light, Depression, and Bipolar Disorder

Chris Aiken, MD Kellie Newsome, PMH-NP
depression
December 4th 2024

Which Patients Respond to Ketamine vs ECT for Treatment-Resistant Depression?

Kenneth J. Bender, PharmD, MA
patients
November 26th 2024

Moving Along

Dinah Miller, MD
© 2024 MJH Life Sciences

All rights reserved.